Accurius Therapeutics Awarded Prestigious NIH FastTrack Grant

January 03, 2024 03:00 AM AEDT | By EIN Presswire
 Accurius Therapeutics Awarded Prestigious NIH FastTrack Grant
Image source: EIN Presswire

Funds will be used to further develop novel oncolytic virus targeted at lung cancer

BOSTON, MA, UNITED STATES, January 2, 2024 /EINPresswire.com/ -- Accurius Therapeutics, a developer of highly targeted oncolytic immunotherapies, is pleased to announce that they have been awarded $2.4 million non-dilutive NIH grant to pursue research that aligns with NIH’s mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. With the initial grant comes an opportunity for an additional $4.5 million non-dilutive grant from the NIH to pursue research with direct clinical applications.

The initial grant funds will be used to accelerate the development of a first of a kind inhalable, engineered, oncolytic immunotherapy based on the Influenza A Virus (eIAV) for the treatment of metastatic Non-Small Cell Lung Cancer (mNSCLC) and other cancers metastatic to the lung. The agent selectively infects and destroys cancer cells while sparing healthy cells and activates the body’s own anti-tumor immune response.

“Despite the significant impact that PD-1 antibody immunotherapy has had on non-small lung cancer survival, the vast majority of patients do not benefit,” states Keith Flaherty M.D., Co-leader of Developmental Therapeutics at the Dana Farber / Harvard Cancer Center. “Accurius is pursuing products and delivery technologies that could potentiate immune responses and expand on the impact that our current immunotherapies have without increasing autoimmune side effect risk. Additionally, the Accurius eIAV could become the combination of choice for checkpoint inhibitors if the preclinical profile is realized in the clinic.”

The Accurius virus is based on groundbreaking work by leading researchers at Memorial Sloan Kettering Cancer Center and the Icahn School of Medicine at Mount Sinai. Company leadership has decades of experience guiding new oncology products and platforms from ideation through FDA approval and clinical use in both cancer treatment and detection. For more information on Accurius, its founders, and the science behind their novel oncolytic immunotherapy, please visit www.accurius.com.

Investor and Scientific inquiries
Mallik Srivatsan, Ph.D., MBA
Co-Founder and Chief Executive Officer
[email protected]
857.260.8126

Kirk Mundy
Chief Commercial Officer
+1 937-344-3292
[email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.